James D. Crapo,1 Abhya Gupta,2 David A. Lynch,1 Jens Vogel-Claussen,3 Henrik Watz,4 Alice M. Turner,5 Robert Mroz,6,7 Wim Janssens,8 Andrea Ludwig-Sengpiel,9 Markus Beck,2 Harald Koegler,10 Bérengère Langellier,11 Anastasia Eleftheraki,2 Frank Risse,2 Claudia Diefenbach2
1National Jewish Health, Denver, CO; 2Boehringer Ingelheim International GmbH, Biberach an der Riss, Germany; 3Diagnostic and Interventional Radiology, Hannover Medical School, Biomedical Research in Endstage and Obstructive Lung Disease Hannover (BREATH), German Center for Lung Research, Hannover, Germany; 4Pulmonary Research Institute at LungClinic Grosshansdorf, German Center for Lung Research, Grosshansdorf, Germany; 5Institute for Applied Health Research, University of Birmingham, Birmingham, United Kingdom; 6Centrum Medycyny Oddechowej, Bialystok, Poland; 72nd Department of Chest Disease and Tuberculosis, Medical University of Bialystok, Bialystok, Poland; 8Laboratory of Respiratory Diseases and Thoracic Surgery, Department of Respiratory Medicine, University Hospital Leuven, KU Leuven, Leuven, Belgium; 9KLB Gesundheitsforschung Lübeck GmbH, Lübeck, Germany; Biberach an der Riss, Germany; 10Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany; 11Boehringer Ingelheim France, Paris, France
Background
- An understanding of COPD phenotypes, pathogenesis and disease progression is needed to facilitate the development of drugs to slow COPD advancement
- Biomarkers may help to characterize COPD and to predict and monitor disease course
- FOOTPRINTS® is an ongoing, 3-year, prospective, longitudinal study investigating soluble and imaging biomarkers, as well as clinical parameters potentially associated with COPD (and in particular emphysema) progression
Abbreviations: COPD, chronic obstructive pulmonary disease.